Compare iShares MSCI Taiwan ETF (EWT) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Hinge Health Inc. Class A Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $108.02 (market cap $12.16B), while Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B). The key difference: iShares MSCI Taiwan ETF is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Taiwan ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EWT | HNGE | |
|---|---|---|
Market Cap | $12.16B | $8.47B |
Volume | 3,390,174 | 1,624,526 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $105.14 |
52-Week Low | $60.03 | $31.17 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $8.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
